ライフサイエンスコーパス: Takeda

1 Welfare, and Family Affairs of South Korea; Takeda.

2 tion of Anion Relay Chemistry (ARC) with the Takeda and Hiyama palladium-mediated cross-coupling proc

3 wa, Kouetsu Ogasawara, Ko Okumura, Kazuyoshi Takeda, and Hideo Yagita approve the retraction.

4 Exelixis in partnership with Ipsen, Takeda, and Roche.

5 TAK-013 (sufugolix; developed previously by Takeda Chemical Industries) as a tool to elucidate the m

6 hnology Commission of Shanghai Municipality; Takeda China; Hasten Biopharmaceutic; Genesis Medtech; P

7 , small-molecule inhibitor of GRK2 and GRK3, Takeda compound 101 (Cmpd101; 3-[[[4-methyl-5-(4-pyridyl

8 Both balanol and the Takeda compounds induce a slight closure of the kinase d

9 This research was sponsored by Takeda Development Center Americas, Inc.

10 Takeda Development Center Americas, Inc., provided fundi

11 In this issue of Neuron, Takeda et al. (2015) use a combination of modern recordi

12 In this issue of the JCI, Takeda et al. describe a novel epigenetic link between M

13 In this issue of JEM, Davidson et al. and Takeda et al. independently report on a dominant negativ

14 Takeda G protein receptor 5 (TGR5), a G protein-coupled

15 s of the antiinflammatory bile acid receptor Takeda G protein-coupled receptor 5 (TGR5) and were part

16 whether an increase in bile acids activates Takeda G protein-coupled receptor 5 (TGR5) in the NTS an

17 ainst hepatic inflammation and injury, while Takeda G protein-coupled receptor 5 (TGR5) promotes adip

18 e nuclear farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor 5 (TGR5).

19 ed CBAs activate a signaling axis containing Takeda G protein-coupled receptor 5, phosphorylated cAMP

20 n colon and that bile salt receptors VDR and Takeda G-protein coupled receptor5 (TGR5) were highly ex

21 We show that CA7S is a Takeda G-protein receptor 5 (TGR5) agonist that increase

22 ion of the G-protein coupled receptor (GPCR) Takeda G-protein receptor 5 (TGR5), also known as G-prot

23 farnesoid X receptor (FXR) and the membrane Takeda G-protein receptor 5 (TGR5), are known to improve

24 n of a ciliary-localized bile acid receptor, Takeda G-protein-coupled receptor 5 (TGR5), the activati

25 rotein-coupled bile acid receptor 1 (GPBAR1; Takeda G-protein-coupled receptor 5 [TGR5]), and cystein

26 xr) and membrane G-protein-coupled receptor (Takeda G-protein-coupled receptor 5; Tgr5).

27 The Takeda-G-protein-receptor-5 (TGR5) mediates physiologica

28 Effects of DCA were mimicked by the Takeda GPCR 5 agonist, INT-777 (50 muM), but not by the

29 and HbetaD2 release from wild-type, but not Takeda GPCR 5(-/-), mice.

30 NIH, NCI, NCTN, Millennium Pharmaceuticals, Takeda Oncology Company, and Celgene Corporation.

31 Takeda Oncology, the National Institutes of Health, and

32 ceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

33 harmaceuticals (a wholly owned subsidiary of Takeda Pharmaceutical Company), and Seagen.

34 harmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company.

35 harmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical International Company.

36 ina Hospital; Sichuan Credit Pharmaceutical; Takeda Pharmaceuticals China; the George Institute for G

37 inase inhibitor, which ultimately became the Takeda Pharmaceuticals clinical candidate TAK-020.

38 Seattle Genetics Inc and Takeda Pharmaceuticals International Co.

39 elgene International, Janssen Pharmaceutica, Takeda Pharmaceuticals International, and Gilead Science

40 Seattle Genetics and Takeda Pharmaceuticals International.

41 Several lead compounds developed by Takeda Pharmaceuticals show high selectivity for GRK2 an

42 ga, a second-generation vaccine developed by Takeda Pharmaceuticals, is therefore timely, but the pot

43 aceuticals Inc, a wholly owned subsidiary of Takeda Pharmacuetical Company Limited, and National Inst

44 IgA]) immune responses in a phase 2 trial of Takeda's bivalent norovirus virus-like particle (VLP) va

45 bility of antibodies produced in response to Takeda's dengue vaccine candidate, TAK-003, to fix C1q a

46 phalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003.

47 Takeda's dengue vaccine is under evaluation in an ongoin

48 Takeda's dengue vaccine is under evaluation in an ongoin

49 Takeda's live attenuated tetravalent dengue vaccine cand

50 ses in sera from a phase 2 clinical trial of Takeda's live-attenuated tetravalent dengue vaccine cand

51 ort 2-year persistence of immune response to Takeda's prophylactic purified formalin-inactivated whol

52 During 2 years of phase 3, Takeda's TAK-003, a chimeric DENV 2 tetravalent vaccine,

53 NCT02747927.Takeda's tetravalent dengue vaccine (TAK-003) continued

54 eport long-term safety and immunogenicity of Takeda's tetravalent dengue vaccine candidate (TAK-003)

55 eport long-term safety and immunogenicity of Takeda's tetravalent dengue vaccine candidate (TAK-003)

56 herapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, VanquaBio, Verily, Voyager Therapeuti